AtriCure, Inc.

NasdaqGM:ATRC Voorraadrapport

Marktkapitalisatie: US$1.8b

AtriCure Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Mike Carrel

Algemeen directeur

US$8.7m

Totale compensatie

Percentage CEO-salaris9.2%
Dienstverband CEO12yrs
Eigendom CEO1.4%
Management gemiddelde ambtstermijn7.8yrs
Gemiddelde ambtstermijn bestuur7.7yrs

Recente managementupdates

Recent updates

A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb

Nov 06
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb

US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results

Nov 01
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

Oct 31
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price

Oct 02
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price

Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce

Sep 06
Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce

Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

Jul 25

AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15
AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02
Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09
What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06
Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02
An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Analyse CEO-vergoeding

Hoe is Mike Carrel's beloning veranderd ten opzichte van AtriCure's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$39m

Jun 30 2024n/an/a

-US$40m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$9mUS$804k

-US$30m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$38m

Dec 31 2022US$8mUS$795k

-US$46m

Sep 30 2022n/an/a

-US$56m

Jun 30 2022n/an/a

US$53m

Mar 31 2022n/an/a

US$52m

Dec 31 2021US$8mUS$766k

US$50m

Sep 30 2021n/an/a

US$45m

Jun 30 2021n/an/a

-US$57m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$6mUS$718k

-US$48m

Sep 30 2020n/an/a

-US$46m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$46m

Dec 31 2019US$6mUS$740k

-US$35m

Sep 30 2019n/an/a

-US$23m

Jun 30 2019n/an/a

-US$20m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018US$4mUS$714k

-US$21m

Sep 30 2018n/an/a

-US$20m

Jun 30 2018n/an/a

-US$20m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$4mUS$671k

-US$27m

Compensatie versus markt: De totale vergoeding ($USD 8.75M ) Mike } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.36M ).

Compensatie versus inkomsten: De vergoeding van Mike is gestegen terwijl het bedrijf verliesgevend is.


CEO

Mike Carrel (53 yo)

12yrs

Tenure

US$8,749,289

Compensatie

Mr. Michael H. Carrel, also known as Mike, serves as the Chief Executive Officer and President at AtriCure, Inc. since November 2012. Mr. Carrel has been Director at Axonics Inc. since February 27, 2019 an...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Michael Carrel
CEO, President & Director12yrsUS$8.75m1.36%
$ 23.9m
Angela Wirick
Chief Financial Officer4.3yrsUS$2.92m0.29%
$ 5.0m
Douglas Seith
Chief Operating Officer9.8yrsUS$3.50m0.32%
$ 5.6m
Salvatore Privitera
Chief Technical Officer7.8yrsUS$2.13m0.21%
$ 3.8m
Karl Dahlquist
Chief Legal Officer5.7yrsUS$2.13m0.11%
$ 1.9m
Vinayak Doraiswamy
Chief Scientific Officer7.7yrsUS$1.78m0.12%
$ 2.2m
Valerie Storch-Willhaus
Vice President of Corporate Marketing & Communicationsno datageen gegevensgeen gegevens
Justin Noznesky
Chief Marketing & Strategy Officer8.7yrsUS$1.78m0.15%
$ 2.6m
Deborah Yount
Chief Human Resources Officer2.4yrsUS$1.92m0.098%
$ 1.7m

7.8yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ATRC is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Michael Carrel
CEO, President & Director12yrsUS$8.75m1.36%
$ 23.9m
Sven Wehrwein
Independent Director8yrsUS$227.47k0.059%
$ 1.0m
B. Johnson
Independent Director7.7yrsUS$264.97k0.091%
$ 1.6m
Shlomi Nachman
Independent Directorless than a yeargeen gegevens0.027%
$ 474.6k
Robert White
Independent Chairman of the Board11.7yrsUS$225.47k0.20%
$ 3.5m
Karen Prange
Independent Director4.9yrsUS$219.97k0.049%
$ 866.2k
Maggie Yuen
Independent Director3.4yrsUS$209.97k0.018%
$ 324.7k
Regina Groves
Independent Director7.7yrsUS$232.47k0.063%
$ 1.1m
Deborah Telman
Independent Director3.4yrsUS$212.47k0.034%
$ 607.5k

7.7yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ATRC wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).